Volume 24, Number 6—June 2018
CME ACTIVITY - Research
Bioclinical Test to Predict Nephropathia Epidemica Severity at Hospital Admission
Maxime Hentzien
, Stéphanie Mestrallet, Pascale Halin, Laure-Anne Pannet, Delphine Lebrun, Moustapha Dramé, Firouzé Bani-Sadr, Jean-Marc Galempoix, Christophe Strady, Jean-Marc Reynes, Christian Penalba, and Amélie Servettaz
, Stéphanie Mestrallet, Pascale Halin, Laure-Anne Pannet, Delphine Lebrun, Moustapha Dramé, Firouzé Bani-Sadr, Jean-Marc Galempoix, Christophe Strady, Jean-Marc Reynes, Christian Penalba, and Amélie Servettaz
Table 4
Events observed in patients hospitalized with NE by risk group as determined by bioclinical test score, Ardennes Department, France, January 2000–December 2014*
| Risk group | Score | No. NE patients | Observed severe NE, no. (%) |
|---|---|---|---|
| Low | 0–10 | 61 | 2 (3.3) |
| Intermediate | 11–19 | 80 | 14 (17.5) |
| High | 20–45 | 53 | 24 (45.3) |
*Data were missing for 11 patients, who were excluded in this analysis. However, similar results for observed severe NE were obtained when assuming a score of zero for missing data: low (4.7%, 3/64), intermediate (20.1%, 18/87), and high (44.4%, 24/54). The leukocyte count and platelet count at admission were missing from the 1 additional patient with severe NE categorized as low risk in this analysis. NE, nephropathia epidemica.
Page created: May 15, 2018
Page updated: May 15, 2018
Page reviewed: May 15, 2018
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.